Background {#Sec1}
==========

Aside from low-density lipoprotein cholesterol (LDL-C) and triglycerides, lipoprotein(a) (Lp(a)) is an important contributor to atherogenesis \[[@CR1]\]. Lp(a) is a lipoprotein particle comprised of an LDL domain and a covalently bound apolipoprotein(a) (apo(a)). Lp(a) is characterized by a protein content of 26--31%, a long half-life, and an atherothrombotic effect likely due to its selective accumulation within atherosclerotic plaque and its inhibition of the fibrinolytic pathway \[[@CR2]\]. Plasma concentrations of Lp(a) are an independent risk factor for early atherosclerotic cardiovascular disease \[[@CR3]--[@CR5]\]. Lp(a) is a low-density lipoprotein-like substance with a core of cholesteryl esters and a surface layer of phospholipids and unesterified cholesterol that contains a single molecule of apolipoprotein B-100 bound to a molecule of apo(a) by a disulfide linkage \[[@CR6]\]. Values of plasma Lp(a) levels of more than 30 mg/dL are considered elevated \[[@CR7], [@CR8]\], and are associated with increased risk of atherogenesis and cardiovascular disease, especially when exceeding 50 mg/dL \[[@CR9]\]. A single molecule of apo(a) is secreted by the liver and has a structure similar to plasminogen but without protease activity \[[@CR10]\]. In addition to the atherogenic properties afforded by the presence of apoB-100, the apo(a) component of Lp(a) confers thrombogenic effects to the particle \[[@CR11]\]. A growing body of evidence for an atherogenic and pro-thrombotic effect of Lp(a) has been reported, as well as its likely causal association with risk of coronary heart disease and stroke \[[@CR12], [@CR13]\]. Thus, therapeutic strategies to reduce plasma Lp(a) concentrations in patients with hyper-Lp(a) are particularly important to reduce cardiovascular mortality. In this regard, various therapeutic interventions for lowering Lp(a) levels have been reported, including apheresis techniques, nicotinic acid, statins, fibrates, and aspirin, among others \[[@CR14]--[@CR17]\]. It has been reported that plasma Lp(a) levels are decreased by monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) \[[@CR18]--[@CR21]\]. PCSK9 inhibitors act by increasing the density of LDL receptors on the surface of hepatocytes, which subsequently causes a marked reduction of plasma LDL and LDL-apoB \[[@CR22]--[@CR24]\]. Since the availability of LDL-apoB plays a key role in the formation of Lp(a) particles \[[@CR25]\], LDL-lowering activity of PCSK9 inhibitors is accompanied by a significant fall in plasma Lp(a) levels, as suggested by pooled analyses and meta-analyses \[[@CR22]--[@CR24]\]. Several lines of clinical evidence have also shown that statins and fibrates, as the most widely used lipid-lowering drug classes, can lower plasma Lp(a) concentrations \[[@CR14]\]. However, evidence from comparative trials has not been conclusive.

Mixed dyslipidemia is characterized by high serum concentrations of total and LDL-C as well as of triglycerides \[[@CR26]\]. Statins and fibrates are among the first-line pharmacotherapies for mixed dyslipidemia. Findings of clinical trials have shown that the combination of statins and fibrates results in a significantly greater reduction in LDL-C and triglyceride levels and greater increases in high-density lipoprotein cholesterol (HDL-C) compared with monotherapy with either drug \[[@CR27]\]. In addition, both statins and fibrates have been shown to reduce cardiovascular morbidity and mortality \[[@CR28], [@CR29]\]. Moreover, these classes of drug affect different aspects of lipoprotein metabolism. Fibrates decrease serum levels of cholesterol and triglycerides and increase HDL-C levels in hyperlipidemic patients, thereby reducing the risk of developing atherosclerosis \[[@CR30]\]. The main mechanisms of action of fibrates are induction of lipoprotein lipolysis \[[@CR31]\], induction of hepatic fatty acid uptake and reduction of hepatic triglyceride production \[[@CR32], [@CR33]\], enhancement of hepatic removal of LDL particles \[[@CR34]\], reduction of plasma triglyceride-rich lipoproteins \[[@CR35]\], and elevation of HDL production \[[@CR36]\].

Statins mainly act through enhancement of plasma clearance of LDL and reduction of hepatic very low-density lipoprotein production \[[@CR37]\]. Statins reduce hepatic cholesterol biosynthesis through inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase, causing depletion of intracellular cholesterol content and resulting in an increase in the expression and density of hepatic LDL receptors \[[@CR38]\].

Owing to the importance of Lp(a) as an emerging coronary risk factor, and the wide use of statins and fibrates in the management dyslipidemias, the present study aimed to compare the effects of these two classes of drugs on plasma Lp(a) concentrations through a systematic review and meta-analysis of head-to-head clinical trials. A secondary aim was to assess if combination therapy with statins and fibrates is associated with a greater effect on plasma Lp(a) levels compared with monotherapy with either of the agents.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This study was designed in accordance with the instructions of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement \[[@CR39]\]. SCOPUS (<http://www.scopus.com>) and Medline (<http://www.ncbi.nlm.nih.gov/pubmed>) databases were searched using the following search terms in titles and abstracts (also in combination with MESH terms): (rosuvastatin OR pravastatin OR fluvastatin OR simvastatin OR atorvastatin OR pitavastatin OR lovastatin OR cerivastatin) AND (fenofibrate OR bezafibrate OR clofibrate OR ciprofibrate OR gemfibrozil OR "fibric acid" OR "clofibric acid" OR procetofen) AND (lipoprotein(a) OR "lipoprotein (a)" OR Lp(a) OR "Lp (a)"). The wild-card term "\*" was used to increase the sensitivity of the search strategy. The search was limited to studies in human. The literature was searched from inception to October 3, 2016.

Study selection {#Sec4}
---------------

Trials comparing the effects of statins versus fibrates on serum/plasma concentrations of Lp(a) were included in this meta-analysis. Non-interventional studies and studies not providing sufficient information on baseline or follow-up Lp(a) concentrations were excluded from the meta-analysis. Before excluding a study for the latter, the author(s) were contacted and asked to provide the necessary data.

Quality assessment {#Sec5}
------------------

Risk of bias in the studies considered in this meta-analysis was evaluated according to the Cochrane instructions \[[@CR40]\]. Selection bias, performance bias, attrition bias, detection bias, reporting bias, and other sources of bias were judged to be high, low, or unclear in each of the included studies.

Data extraction {#Sec6}
---------------

Studies meeting the inclusion criteria were reviewed and data regarding authors, study location, publication date, number of studied population, trial design, dose and duration of intervention, control group allocation, baseline characteristics of studied population (including age, sex, systolic and diastolic blood pressure, body mass index (BMI), and plasma lipid concentrations), and changes in plasma concentrations of Lp(a). When the values were only presented graphically, GetData Graph Digitizer 2.24 software (<http://getdata-graph-digitizer.com/>) was used to digitize and extract the data.

Quantitative data synthesis {#Sec7}
---------------------------

Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) \[[@CR41]\] and Review Manager, version 5.2 (Cochrane Collaboration) were used for statistical procedures. All reported Lp(a) concentrations were harmonized in mg/dL. Inverse variance-weighted standardized mean difference and 95% confidence intervals (CIs) were used as the summary statistic, considering a correlation coefficient (R) of 0.5. Conversion of median and inter-quartile range to mean and standard deviation was performed as suggested by Hozo et al. \[[@CR42]\]. When plasma Lp(a) levels were presented in multiple time points, data belonging to the longest duration of treatment was included in the meta-analysis. Meta-analysis was performed using a random-effects model (using DerSimonian--Laird method) and the generic inverse variance weighting method. Heterogeneity was quantitatively assessed using *I* ^*2*^ index and Cochrane Q. Sensitivity analysis was performed using the leave-one-out method \[[@CR43]--[@CR46]\]. A subgroup analysis was conducted to explore the impact of treatment duration (\<12 weeks vs. ≥ 12 weeks) on plasma Lp(a) concentrations.

Meta-regression {#Sec8}
---------------

Random effects meta-regression was performed using the unrestricted maximum likelihood method to evaluate the association between calculated weighted mean differences (WMD) in plasma Lp(a) concentrations and duration of treatment.

Publication bias {#Sec9}
----------------

Presence of publication bias in the meta-analysis was investigated using assessment of Begg's funnel plot and statistical tests as previously described \[[@CR47], [@CR48]\]. The "trim and fill" method was used to adjust the effect size for potential publication bias \[[@CR49]\].

Results {#Sec10}
=======

Flow of included studies {#Sec11}
------------------------

Briefly, after multiple database searches, 880 published studies were identified and the abstracts reviewed; 844 did not meet the inclusion criteria and were excluded. Next, 36 full text articles were carefully assessed and reviewed, of which 20 studies were excluded for not measuring Lp(a) concentrations (*n* = 8), having a non-interventional design (*n* = 1), being non-original research (*n* = 1), presenting incomplete data (*n* = 3), lack of statin treatment arm (*n* = 1), lack of fibrate treatment arm (*n* = 3), having an inappropriate control group (*n* = 2), and duplicate reporting (*n* = 1). Finally, 16 studies with 19 treatment arms were found to be eligible and included in the systematic review and meta-analysis. The study selection process is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of the number of studies identified and included into the meta-analysis

Characteristics of included studies {#Sec12}
-----------------------------------

A total of 1388 individuals were recruited in the 15 randomized controlled studies, including 588, 587, and 213 subjects in the fibrate monotherapy, statin monotherapy, and statin/fibrate combination therapy arms (participants of the cross-over trials were considered in both fibrate and statin monotherapy arms), respectively (Table [1](#Tab1){ref-type="table"}). Included studies were published between 1994 and 2009. The clinical trials used different types and doses of fibrates and statins and evaluated atorvastatin 10 mg/day (*n* = 2) \[[@CR50], [@CR51]\], atorvastatin 20 mg/day (*n* = 1) \[[@CR52]\], atorvastatin 40 mg/day (*n* = 1) \[[@CR53]\], simvastatin 10 mg/day (*n* = 1) \[[@CR54]\], simvastatin 20 mg/day (*n* = 5) \[[@CR55]--[@CR59]\], pravastatin 40 mg/day (*n* = 1) \[[@CR60]\], lovastatin 10 mg/day (*n* = 1) \[[@CR61]\], lovastatin 40--80 mg/day (n = 1) \[[@CR62], [@CR63]\], fluvastatin 40 mg/day (*n* = 1) \[[@CR64]\], rosuvastatin 10 mg/day (*n* = 1) \[[@CR65]\], fenofibrate 200 mg/day (*n* = 5) \[[@CR50]--[@CR52], [@CR59], [@CR65]\], fenofibrate 145 mg/day (*n* = 1) \[[@CR53]\], fenofibrate 160 mg/day (*n* = 1) \[[@CR57]\], gemfibrozil 1200 mg/day (*n* = 6) \[[@CR54], [@CR55], [@CR58], [@CR60], [@CR62], [@CR63]\], and bezafibrate 400 mg/day (*n* = 3) \[[@CR56], [@CR61], [@CR64]\]. The range of intervention periods was from 8 weeks \[[@CR60], [@CR61]\] to 24 weeks \[[@CR52]\]. Study designs of included studies were cross-over \[[@CR51], [@CR54], [@CR60], [@CR61]\] and parallel-group \[[@CR53], [@CR55]--[@CR59], [@CR62]--[@CR65]\]. Selected trials enrolled subjects with diabetes \[[@CR52], [@CR54], [@CR57]\], combined hyperlipidemia \[[@CR50]--[@CR59], [@CR62], [@CR63]\], familial defective apoB \[[@CR60]\], heart transplantation \[[@CR61]\], primary dyslipoproteinemia \[[@CR54]\], mixed dyslipidemia combined with hyper-Lp(a) \[[@CR62]\], primary hypercholesterolemia combined with hyper-Lp(a) \[[@CR63]\], primary hypercholesterolemia \[[@CR64], [@CR65]\], and primary hypertriglyceridemia \[[@CR65]\].Table 1Demographic characteristics of the included studiesAuthorStudy designTarget PopulationTreatment duration*n*Study groupsAge, yearsFemale, *n* (%)BMI, kg/m^2^Total cholesterol, mg/dLLDL-C, mg/dLHDL-C, mg/dLTriglycerides, mg/dLLp(a), mg/dLLp(a) change, mg/dLAthyros et al. (2002) \[[@CR52]\]Randomized, open-label trialType 2 diabetes and combined hyperlipidemia24 weeks40\
40\
40Atorvastatin 20 mg/day\
Fenofibrate 200 mg/day\
Atorvastatin 20 mg/day + fenofibrate 200 mg/day57 (44--67)^a^\
58 (48--69)^a^\
58 (50--68)^a^17 (42.5)\
18 (45.0)\
17 (42.5)ND\
ND\
ND252 ± 17\
253 ± 17\
255 ± 19161 ± 15\
163 ± 15\
163 ± 1634.6 ± 3.2\
34.8 ± 3.4\
35.1 ± 3.5278 ± 24\
281 ± 24\
278 ± 2318.4 ± 3.7\
20.1 ± 5.2\
19.2 ± 4.12.0\
--4.0\
1.0Bredie et al. (1996) \[[@CR55]\]Randomized, double-blind, placebo-controlled trialFamilial combined hyperlipidemia12 weeks41\
40Simvastatin 20 mg/day Gemfibrozil 1200 mg/day50.4 ± 10.8\
53.4 ± 9.49 (21.9)\
14 (35.0)26.6 ± 2.7\
27.2 ± 3.0282.2 ± 37.1\
290.0 ± 37.8149.6 ± 37.8\
157.7 ± 38.232.4 ± 7.3\
35.1 ± 7.7283.4 ± 106.2\
285.2 ± 108.019.6^b^\
18.0^b^6.5\
2.7Hansen et al. (1994) \[[@CR60]\]Randomized, cross-over trialFamilial defective apolipoprotein\
B-1008 weeks17\
13Pravastatin 40 mg/day\
Gemfibrozil 1200 mg/day45.8 ± 17.1\
40.8 ± 12.312 (70.5)\
7 (53.8)ND\
ND320.9 ± 58.0\
320.9 ± 46.4247.4 ± 54.1\
235.8 ± 42.546.4 ± 7.7\
50.2 ± 19.3115.1 (79.7--168.2)^a^\
141.7 (106.2--230.2)^a^10.5 (3.5--16.7)^a^\
8.3 (3.4--12.9)^a^0.9\
1.1Perez-Jimenez et al. (1995)\
\[[@CR61]\]Randomized, cross-over trialPatients with heart transplant8 weeks18\
18Lovastatin 10 mg/day\
Bezafibrate 400 mg/day54 ± 22 (11.1)ND302 ± 7\
307 ± 5213 ± 5\
212 ± 554 ± 3\
51 ± 4170 ± 15\
201 ± 1734 ± 9\
37 ± 95.0\
--13.0Melenovsky et al. (2002)\
\[[@CR51]\]Randomized, open-label, cross-over trialCombined hyperlipidemia10 weeks15\
14Fenofibrate 200 mg/day\
Atorvastatin 10 mg/day48.0 ± 6.9\
46.4 ± 8.9ND\
ND27.7 ± 2.3\
27.9 ± 3.2300.0 ± 56.4\
283.0 ± 35.9174.7 ± 46.4\
165.8 ± 23.249.4 ± 8.8\
47.9 ± 15.8492.4 ± 440.2\
465.0 ± 372.824 ± 29\
17 ± 232.8\
1.8Ohrvall et al. (1995) \[[@CR54]\]Randomized, double-blind, cross-over trialDiabetes and hyperlipo-proteinemia4 months25\
24Gemfibrozil 1200 mg/day\
Simvastatin 10 mg/day63.7 (48--78)^a^9 (31.0)ND232.0 ± 40.2152.7 ± 43.336.7 ± 6.9116.0 ± 52.537.77 ± 54.75--7.0\
--2.4Ramires et al. (1995) \[[@CR62]\]Randomized clinical trialHyperlipidemia and hyperlipo-proteinemia12 weeks14\
13Gemfibrozil 1200 mg/day\
Lovastatin 40-80 mg/day54 ± 7\
55 ± 95 (55.5)\
3 (30.0)ND\
ND298.9 ± 12.3\
299.3 ± 11.2209.9 ± 20.8\
208.0 ± 11.931.7 ± 7.3\
34.4 ± 6.1295.8 ± 23.0\
281.6 ± 20.329.8 ± 5.7\
27.8 ± 4.1--7.5\
1.4Bairaktari et al. (1999) \[[@CR50]\]Open-label trialMixed hyperlipidemia16 weeks45\
46Atorvastatin 10 mg/day\
Fenofibrate 200 mg/day49 ± 8\
46 ± 1016 (35.5)\
15 (32.6)26.8 ± 4\
27.4 ± 3278 ± 34\
282 ± 37198 ± 29\
199 ± 3640 ± 11\
36 ± 16271 ± 59\
269 ± 6014 ± 12\
11.8 ± 10.51.2\
--1.8Davidson et al. (2009) \[[@CR53]\]Randomized, double-blind trialDyslipidemia12 weeks74\
73\
73Atorvastatin 40 mg/day\
Fenofibrate 145 mg/day\
Atorvastatin 40 mg/day + fenofibrate 100 mg/day56.3 ± 9.8\
56.4 ± 10.5\
54.9 ± 10.739 (52.7)\
33 (45.2)\
33 (45.2)ND\
ND\
ND254.4 ± 44.2\
251.9 ± 47.5\
252.0 ± 40.1165.0 ± 37.7\
166.6 ± 46.7\
156.2 ± 33.642.7^b^\
41.2^b^\
43.3^b^265.1^b^\
227.3^b^\
270.2^b^69.0 ± 67.5\
66.0 ± 65.3\
76.8 ± 74.59.3\
5.1\
6.9Greten et al. (1994) \[[@CR64]\]Randomized, double-blind trialPrimary hypercholesterolemia12 weeks64\
67Fluvastatin 40 mg/day\
Bezafibrate 400 mg/day53.0 (18--75)^a^\
51.8 (22--70)^a^37 (57.8)\
37 (55.2)24.6 (18.6--31.2)^a^\
24.7 (16.9--31.6)^a^352.7 ± 89.4\
340.3 ± 76.7268.9 ± 88.5\
257.4 ± 75.655.2 ± 12.2\
55.2 ± 12.6143.2 ± 48.0\
138.0 ± 59.412.0 ± 16.5\
14.0 ± 30.01.0\
0.4Kehely et al. (1995) \[[@CR56]\]Randomized, double-blind trialMixed hyperlipidemia3 months53\
27\
26Placebo\
Simvastatin 20 mg/day\
Bezafibrate 400 mg/dayND\
52 ± 9\
49 ± 10ND\
11 (40.7)\
4 (15.3)ND\
ND\
ND298.5 ± 51.8189.0 ± 54.942.5 ± 8.1286.9 ± 122.219.8 ± 2.85.7\
--2.5May et al. (2008) \[[@CR57]\]Randomized, double-blind, placebo-controlled trialDiabetes and mixed dyslipidemia12 weeks100\
100\
100Fenofibrate 160 mg/day\
Simvastatin 20 mg/day\
Fenofibrate 160 mg/day +\
Simvastatin 20 mg/day61.6 ± 11.5135 (45.0)NDND\
ND\
NDND\
ND\
NDND\
ND\
NDND\
ND\
ND4.0 (2.0--6.0)^a^\
4.0 (2.0--6.0)^a^\
5.0 (3.0--9.0)^a^1.0\
1.0\
0.0Ramires et al. (1997) \[[@CR63]\]Randomized clinical trialHypercholesterolemia and hyperlipoproteinemia12 weeks14\
13Gemfibrozil 1200 mg/day\
Lovastatin 40-80 mg/day54 ± 7\
55 ± 95 (36.0)\
6 (59.0)ND\
ND306 ± 13\
307 ± 11215 ± 21\
213 ± 1233 ± 7\
35 ± 6294 ± 23\
280 ± 2051 ± 10\
48 ± 7--13.0\
--2.0Saougos et al. (2007) \[[@CR65]\]Clinical trialHyperlipidemia2 months50\
50Rosuvastatin 10 mg/day\
Fenofibrate 200 mg/day54.6 ± 14.6\
55.9 ± 1131 (62.0)\
30 (60.0)25.8 ± 4.2\
34.3 ± 7297.7 ± 50.2\
235.8 ± 34.8208.8 ± 42.5\
146.9 ± 34.858.0 ± 11.6\
50.2 ± 11.6141.7 ± 53.1\
239.1 ± 53.14.0 (2.0--7.4)^a^\
3.8 (2.0--7.9)^a^0.0\
0.1Vigna et al. (1999) \[[@CR58]\]Randomized, double-blind trialMen with mixed hyperlipidemia2 months15\
15Gemfibrozil 1200 mg/day\
Simvastatin 20 mg/day53.6 ± 11.7\
50.9 ± 9.90 (0.0)\
0 (0.0)26.7 ± 1.9\
25.0 ± 2.5280.2 ± 30.1\
281.2 ± 38.8208.5 ± 30.1\
206.7 ± 37.846.1 ± 9.9\
44.4 ± 8.246.1 ± 9.9\
44.4 ± 8.225.7 ± 22.6\
9.2 ± 11.8--4.3\
2.1de Lorgeril et al. (1999) \[[@CR59]\]Randomized, double-blind trialDyslipidemic coronary patients12 weeks32\
32Fenofibrate 200 mg/day\
Simvastatin 20 mg/dayNDNDND278.4 ± 27.0\
278.4 ± 27.0193.3 ± 27.0\
197.2 ± 23.246.4 ± 11.6\
46.4 ± 7.7186.0 ± 79.7\
168.2 ± 88.534 ± 62\
32 ± 39--6.0\
--2.0Values are expressed as mean ± SD^a^Median (interquartile range)^b^Mean only*BMI* body mass index, *ND* no data

Lp(a) assay methods {#Sec13}
-------------------

Different assays methods were used to measure plasma Lp(a) concentrations. On this regard, some studies \[[@CR50], [@CR52], [@CR56], [@CR61], [@CR65]\] measured Lp(a) levels in plasma using an enzyme-linked immunosorbent assay with a monoclonal anti-Lp(a) antibody (Terumo Medical, Elktron, MD). Other trials \[[@CR54], [@CR55], [@CR60], [@CR62], [@CR63]\] determined Lp(a) concentrations by measuring the apoprotein(a) moiety in a commercially solid-phase two-site immunoradiometric assay using two different specific anti-apoprotein(a) monoclonal antibodies (Pharmacia, Uppsala, Sweden). Melenovky et al. \[[@CR51]\] measured serum levels of Lp(a) by Laurell rocket immunoelectrophoresis using a commercial antisera (Immuno, Austria). Davidson et al. \[[@CR53]\] measured Lp(a) concentrations by nuclear magnetic resonance (LipoScience Inc., Raleigh, North Carolina). Vigna et al. \[[@CR58]\] determined Lp(a) levels by enzyme-linked immunosorbent assay with a polyclonal anti-apoprotein(a) antibody (Italiana Laboratori Bouty S.p.A., Milan, Italy). Three studies did not specify the method used to determine plasma Lp(a) concentrations \[[@CR57], [@CR59], [@CR64]\]. Finally, all included studies were characterized by a lack of sufficient information regarding the allele-specific assay (Table [2](#Tab2){ref-type="table"}).Table 2Methods used to measure Lp(a) in included studiesStudyMethodKringle assayAthyros et al. (2002) \[[@CR52]\]ELISANSBredie et al. (1996) \[[@CR55]\]IRANSHansen et al. (1994) \[[@CR60]\]IRANSPerez-Jimenez et al. (1995) \[[@CR61]\]ELISANSMelenovsky et al. (2002) \[[@CR51]\]IEPNSOhrvall et al. (1995) \[[@CR54]\]IRANSRamires et al. (1995) \[[@CR62]\]IRANSBairaktari et al. (1999) \[[@CR50]\]ELISANSDavidson et al. (2009) \[[@CR53]\]NMRNSGreten et al. (1994) \[[@CR64]\]NSNSKehely et al. (1995) \[[@CR56]\]ELISANSMay et al. (2008) \[[@CR57]\]NSNSRamires et al. (1997) \[[@CR63]\]IRANSSaougos et al. (2007) \[[@CR65]\]ELISANSVigna et al. (1999) \[[@CR58]\]ELISANSde Lorgeril et al. (1999) \[[@CR59]\]NSNS*ELISA* enzyme-linked immunosorbent assay, *IRA* immunoradiometric assay, *IEP* immunoelectrophoresis, *NMR* nuclear magnetic resonance, *NS* not specified

Quality assessment {#Sec14}
------------------

Most of the included studies were characterized by lack of information about the random sequence generation, allocation concealment, blinding of outcome assessment, and blinding of participants and personnel. On this regard, several trials showed high risk of bias for blinding of participants and personnel. Also, some studies had other biases related with the study design. However, almost all evaluated studies showed low risk of bias according to selective outcome reporting. Details of the quality of bias assessment are shown in Table [3](#Tab3){ref-type="table"}.Table 3Quality of bias assessment of the included studies according to the Cochrane guidelinesStudyRandom sequence generationAllocation concealmentSelective reportingOther biasBlinding of participants and personnelBlinding of outcome assessmentIncomplete outcome dataAthyros et al. (2002) \[[@CR52]\]LULLHULBredie et al. (1996) \[[@CR55]\]UULLUULHansen et al. (1994) \[[@CR60]\]UULLHULPerez-Jimenez et al. (1995) \[[@CR61]\]UULUHULMelenovsky et al. (2002) \[[@CR51]\]HULUHULOhrvall et al. (1995) \[[@CR54]\]UULLUUURamires et al. (1995) \[[@CR62]\]UULHHUUBairaktari et al. (1999) \[[@CR50]\]HULUUULDavidson et al. (2009) \[[@CR53]\]LLLLLLLGreten et al. (1994) \[[@CR64]\]UULUUULKehely et al. (1995) \[[@CR56]\]UULLUULMay et al. (2008) \[[@CR57]\]LULULUURamires et al. (1997) \[[@CR63]\]UULUUULSaougos et al. (2007) \[[@CR65]\]HULUUULVigna et al. (1999) \[[@CR58]\]UULUUULde Lorgeril et al. (1999) \[[@CR59]\]UUUUUUU*L* low risk of bias, *H* high risk of bias, *U* unclear risk of bias

Quantitative data synthesis {#Sec15}
---------------------------

### Fibrate monotherapy versus statin monotherapy {#Sec16}

In a single-arm analysis of randomized controlled study arms (without control group), statin therapy was found to increase plasma Lp(a) concentrations (WMD, 4.14 mg/dL; 95% CI, 0.15 to 8.12; *P* = 0.042), while the same effect was not observed with fibrates (WMD, 0.64 mg/dL; 95% CI, --1.59 to 2.87; *P* = 0.574). The lp(a)-raising effect of statins in single-arm analysis was diminished after exclusion of the trial with rosuvastatin (WMD, 4.56 mg/dL; 95% CI, --1.09 to 10.22; *P* = 0.113). Combination therapy with statins and fibrates did not exert a significant alteration in plasma Lp(a) concentrations (WMD, 4.52 mg/dL; 95% CI, --7.74 to 16.79; *P* = 0.470) (Fig. [2](#Fig2){ref-type="fig"}). Meta-analysis of data from 15 comparative trials showed a significantly greater effect of fibrates versus statins in reducing plasma Lp(a) concentrations (WMD, --2.70 mg/dL; 95% CI, --4.56 to --0.84; *P* = 0.004) (Fig. [3](#Fig3){ref-type="fig"}). This effect size was robust in sensitivity analysis and the overall estimated effect size was not significantly changed by the omission of a single study (Fig. [3](#Fig3){ref-type="fig"}). In the subgroup analysis, a greater effect of fibrates versus statins in reducing plasma Lp(a) levels was observed in the subset of trials with elevated baseline Lp(a) concentrations (≥30 mg/dL) (WMD, --10.84 mg/dL; 95% CI, --16.66 to --5.03; *P* \< 0.001) compared with trials having baseline Lp(a) levels \< 30 mg/dL (WMD, --2.08 mg/dL; 95% CI, --3.94 to --0.23; *P* = 0.027; *P* = 0.005 for between-subgroup comparison) (Fig. [4](#Fig4){ref-type="fig"}). With respect to treatment duration, the greater effect of fibrates versus statins in reducing plasma Lp(a) levels was observed in the subset of trials with ≥ 12 weeks length (WMD, --3.16 mg/dL; 95% CI, --5.52 to --0.79; *P* = 0.009); yet there was no significant difference between statins and fibrates in the subset of trials with a duration of \< 12 weeks (WMD, +0.09 mg/dL; 95% CI, --0.26 to +0.44; *P* = 0.609; *P* = 0.008 for between-subgroup comparison) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 2Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of fibrates (upper plot), statins (middle plot), and statin/fibrate combinations (lower plot) on plasma Lp(a) concentrations in single-arm uncontrolled trials Fig. 3Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of fibrate versus statin monotherapy on plasma Lp(a) concentrations. Right plot shows leave-one-out sensitivity analysis of the impact of fibrate versus statin monotherapy on plasma Lp(a) concentrations Fig. 4Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of fibrate versus statin monotherapy in studies with baseline Lp(a) concentrations of \< 30 mg/dL and ≥ 30 mg/dL Fig. 5Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of fibrate versus statin monotherapy on plasma Lp(a) concentrations in the subsets of trials \< 12 and ≥ 12 weeks duration

### Statin monotherapy versus statin/fibrate combination therapy {#Sec17}

Meta-analysis of data from five comparative trials showed a significantly greater effect of combination therapy with fibrates and statins versus statin monotherapy in reducing plasma Lp(a) concentrations (WMD, --1.60 mg/dL; 95% CI, --2.93 to --0.26; *P* = 0.019) (Fig. [6](#Fig6){ref-type="fig"}). In the sensitivity analysis, there was a partial sensitivity to the study by May et al. \[[@CR57]\], which resulted in a borderline significant effect size (WMD, --2.06 mg/dL; 95% CI, --4.41 to +0.28; *P* = 0.085) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of statin monotherapy versus statin/fibrate combination therapy on plasma Lp(a) concentrations. Right plot shows leave-one-out sensitivity analysis of the impact of statin monotherapy versus statin/fibrate combination therapy on plasma Lp(a) concentrations

### Fibrate monotherapy versus statin/fibrate combination therapy {#Sec18}

Meta-analysis of data from four comparative trials did not suggest any significant difference between fibrate monotherapy and combination therapy with statins in terms of reducing plasma Lp(a) concentrations (WMD, --1.76 mg/dL; 95% CI, --5.44 to +1.92; *P* = 0.349) (Fig. [7](#Fig7){ref-type="fig"}). This effect size was robust in sensitivity analysis and the overall estimated effect size was not significantly changed by the omission of a single study (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Forest plot detailing weighted mean difference and 95% confidence intervals for the impact of fibrate monotherapy versus statin/fibrate combination therapy on plasma Lp(a) concentrations. Right plot shows leave-one-out sensitivity analysis of the impact of fibrate monotherapy versus statin/fibrate combination therapy on plasma Lp(a) concentrations

Meta-regression {#Sec19}
---------------

Meta-regression analysis was conducted to assess the association between changes in plasma Lp(a) concentrations with duration of treatment with statins and fibrates as a potential moderator. The impact of fibrates versus statins in reducing plasma Lp(a) concentrations was not found to be significantly associated with treatment duration (slope, +0.06; 95% CI, --0.40 to +0.53; *P* = 0.788) (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Meta-regression plots of the association between mean changes in plasma Lp(a) concentrations and duration of treatment. The size of each circle is inversely proportional to the variance of change

Publication bias {#Sec20}
----------------

The funnel plot of the study precision (inverse standard error) by effect size (mean difference) was asymmetric and suggested potential publication bias. Although the results of Begg's rank correlation (Kendall's Tau with continuity correction = 0.02, *Z* = 0.10, two-tailed *P* value = 0.921) was not significant, Egger's linear regression analysis suggested potential publication bias (intercept, --1.63; standard error, 0.76; 95% CI, --3.28 to +0.02; *t* = 3.01; df = 13.00; two-tailed *P* = 0.053). An attempt was made to address publication bias using trim-and-fill correction. Two potentially missing studies on the right side of funnel plot were imputed leading to a corrected effect size that was still significant (WMD, --2.12 mg/dL; 95% CI, --3.95 to --0.29). The "fail safe N" method indicated that 116 theoretically missing studies would be required to make the overall estimated effect size non-significant. Funnel plot of the impact of fibrates versus statins on plasma Lp(a) concentrations is illustrated in Fig. [9](#Fig9){ref-type="fig"}.Fig. 9Funnel plot detailing publication bias in the studies reporting the impact of fibrate versus statin monotherapy on plasma Lp(a) concentrations. Open circles represent observed published studies; closed circles represent imputed unpublished studies

Discussion {#Sec21}
==========

The findings of the present meta-analysis suggest that fibrates are more efficacious than statins in lowering plasma Lp(a) concentrations. In the absence of specific Lp(a)-lowering agents, statins and fibrates have been shown to reduce Lp(a) levels in hyperlipidemic subjects. However, the magnitude of the Lp(a)-lowering effect of these agents relative to each other has not been adequately investigated, and results of head-to-head comparative trials have not been fully clarified. Evidence of beneficial effect of statins on elevated plasma Lp(a) concentrations is still limited and variable \[[@CR14], [@CR66], [@CR67]\]. In our single-arm analysis, statin therapy was found to increase plasma Lp(a) concentrations. This result is in contrast with some previous reports on the Lp(a)-lowering effect of statin therapy. While the limitation of our single-arm analysis in including only trials in which statins and fibrates were concomitantly studied should be considered, a possible reason for the observed increase in plasma Lp(a) concentrations could be attributed to the effect of rosuvastatin. There is evidence from previous trials indicating that, unlike atorvastatin and simvastatin, rosuvastatin therapy may significantly increase plasma Lp(a) levels \[[@CR68], [@CR69]\]. This is consistent with the results of our single-arm analysis, as excluding the only arm with rosuvastatin \[[@CR65]\] from the analysis resulted in a non-significant overall effect of statin therapy on Lp(a) levels. Moreover, the results of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial showed a small but statistically significant positive shift in plasma Lp(a) levels following rosuvastatin therapy. The JUPITER trial also demonstrated that elevated plasma Lp(a) levels are a significant determinant for the residual cardiovascular risk in patients on optimal rosuvastatin therapy \[[@CR70]\].

Statins have been shown to modestly decrease Lp(a) levels in individuals with familial hypercholesterolemia \[[@CR71]\], but the mechanism of this effect remains elusive. This slight reduction could be explained by the strong genetic regulation of Lp(a) expression, as plasma Lp(a) concentration is significantly determined by genetic variability at the apo(a) gene locus or at other closely related loci \[[@CR14]\]. With respect to fibrates, the effect on Lp(a) could be related to the induction of PPAR-α, and subsequent activation of farnesoid X receptor \[[@CR72]\]. Inhibition of apoprotein(a) transcription by farsenoid X receptor has been shown to be mediated via translocation of the receptor to the nucleus, competitive inhibition of the binding of hepatocyte nuclear factor-4-α, and stimulation of fibroblast growth factor 19 expression in the intestine \[[@CR73], [@CR74]\]. Release of fatty acids from adipose tissue is another mechanism that may contribute to the Lp(a)-lowering effect of fibrates \[[@CR55]\], but the specific mechanism remains unclear. Since Lp(a) may be bound to triglyceride-rich lipoproteins \[[@CR75]\], the reduction of triglyceride-rich lipoproteins by fibrates could modify plasma Lp(a) concentrations \[[@CR76]\], although this mechanism needs to be verified.

The results of two recent large randomized outcome trials with fenofibrate, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) \[[@CR77]\] and Action to Control Cardiovascular Risk in Diabetes (ACCORD) \[[@CR78]\], have not supported a benefit of fenofibrate on primary endpoints (myocardial infarction and death from coronary heart disease) in patients with type 2 diabetes taking statin. However, as our analysis revealed, the Lp(a)-lowering effect of fibrates might be more pronounced in individuals with elevated Lp(a) levels at baseline. FIELD and ACCORD trials were not designed to look at Lp(a) changes, and hyper-Lp(a) was not among the inclusion criteria of neither of these trials. Since subanalyses in subjects with atherogenic dyslipidemia in the above-mentioned trials have shown incremental benefits of adding fenofibrate to statin in diabetic patients, similar subanalyses in patients with hyper-Lp(a) could be worthwhile and deserve attention. However, it must be noted that the design in FIELD and ACCORD trials did not involve a head-to-head comparison of statins and fibrates, as opposed to the present meta-analysis.

Some limitations of the present analysis deserve acknowledgment. Several studies included in this meta-analysis did not provide sufficient information about the methods used for random sequence generation, allocation concealment, blinding of outcome assessment, and blinding of participants and personnel, resulting in uncertainty on their overall quality. Overall, there was a small population size in statin/fibrate combination therapy group, leading to a relatively low number of subjects in the pooled analysis; however, sensitivity analysis was conducted using the removal of one study (leave-one-out approach) in order to evaluate the influence of each study on the overall effect size. As another limitation, difference in the dose and duration of treatment as well as assays methods that were used to measure the Lp(a) concentrations might have introduced heterogeneity to the results. In this meta-analysis, the impact of this heterogeneity was tried to be minimized by applying a random-effects model and performing subgroup and meta-regression analyses. Finally, none of the included studies defined elevated Lp(a) concentrations among their inclusion criteria, which necessitates additional studies in patients with hyper-Lp(a).

Conclusion {#Sec22}
==========

In conclusion, results of this meta-analysis suggest that fibrates have a significantly greater effect in reducing plasma Lp(a) concentrations compared with statins. Likewise, addition of fibrates to statins can enhance the Lp(a)-lowering effect of statins. Thus, combination therapy with fibrates and statins can provide an additional beneficial effect in decreasing the risk of developing cardiovascular disease by reducing apo(a) expression and enhancing Lp(a) clearance, especially in the subgroup of patients with hyper-Lp(a). Future investigations are recommended to explore the impact of other conventional Lp(a)-lowering therapies \[[@CR79], [@CR80]\] as well as novel lipid-modifying agents in comparison with fibrates and statins \[[@CR81]--[@CR84]\]. Moreover, further randomized head-to-head trials with different treatment durations could be helpful to clarify if prolongation of treatment could result in further reductions in plasma Lp(a) concentrations.
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